drugset / Trial / NCT04752371
A Study to Evaluate Camoteskimab in Participants With Still's Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.
Timeline
- Start
- 2021-03-25
- Primary completion
- 2022-05-24
- Completion
- 2022-05-24
Outcome
Outcome not reported
Stopped: “Sponsor discretion”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camoteskimab | Monoclonal antibody | 7 mg/kg | Intravenous |